Hypoxia-inducible factor 1 alpha-mediated RelB/APOBEC3B down-regulation allows hepatitis B virus persistence
<p><strong>Background and Aims:</strong> Therapeutic strategies against HBV focus, among others, on the activation of the immune system to enable the infected host to eliminate HBV. Hypoxia‐inducible factor 1 alpha (HIF1α) stabilization has been associated with impaired immune resp...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wolters Kluwer
2021
|
| _version_ | 1797113132408111104 |
|---|---|
| author | Riedl, T Faure-Dupuy, S Rolland, M Schuehle, S Hizir, Z Calderazzo, S Zhuang, X Wettengel, J Lopez, MA Barnault, R Mirakaj, V Prokosch, S Heide, D Leuchtenberger, C Schneider, M Heßling, B Stottmeier, B Wessbecher, IM Schirmacher, P McKeating, JA Protzer, U Durantel, D Lucifora, J Dejardin, E Heikenwalder, M |
| author_facet | Riedl, T Faure-Dupuy, S Rolland, M Schuehle, S Hizir, Z Calderazzo, S Zhuang, X Wettengel, J Lopez, MA Barnault, R Mirakaj, V Prokosch, S Heide, D Leuchtenberger, C Schneider, M Heßling, B Stottmeier, B Wessbecher, IM Schirmacher, P McKeating, JA Protzer, U Durantel, D Lucifora, J Dejardin, E Heikenwalder, M |
| author_sort | Riedl, T |
| collection | OXFORD |
| description | <p><strong>Background and Aims:</strong> Therapeutic strategies against HBV focus, among others, on the activation of the immune system to enable the infected host to eliminate HBV. Hypoxia‐inducible factor 1 alpha (HIF1α) stabilization has been associated with impaired immune responses. HBV pathogenesis triggers chronic hepatitis‐related scaring, leading inter alia to modulation of liver oxygenation and transient immune activation, both factors playing a role in HIF1α stabilization.</p>
<p><strong>Approach and Results:</strong> We addressed whether HIF1α interferes with immune‐mediated induction of the cytidine deaminase, apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B; A3B), and subsequent covalently closed circular DNA (cccDNA) decay. Liver biopsies of chronic HBV (CHB) patients were analyzed by immunohistochemistry and in situ hybridization. The effect of HIF1α induction/stabilization on differentiated HepaRG or mice ± HBV ± LTβR‐agonist (BS1) was assessed in vitro and in vivo. Induction of A3B and subsequent effects were analyzed by RT‐qPCR, immunoblotting, chromatin immunoprecipitation, immunocytochemistry, and mass spectrometry. Analyzing CHB highlighted that areas with high HIF1α levels and low A3B expression correlated with high HBcAg, potentially representing a reservoir for HBV survival in immune‐active patients. In vitro, HIF1α stabilization strongly impaired A3B expression and anti‐HBV effect. Interestingly, HIF1α knockdown was sufficient to rescue the inhibition of A3B up‐regulation and ‐mediated antiviral effects, whereas HIF2α knockdown had no effect. HIF1α stabilization decreased the level of v‐rel reticuloendotheliosis viral oncogene homolog B protein, but not its mRNA, which was confirmed in vivo. Noteworthy, this function of HIF1α was independent of its partner, aryl hydrocarbon receptor nuclear translocator.</p>
<p><strong>Conclusions:</strong> In conclusion, inhibiting HIF1α expression or stabilization represents an anti‐HBV strategy in the context of immune‐mediated A3B induction. High HIF1α, mediated by hypoxia or inflammation, offers a reservoir for HBV survival in vivo and should be considered as a restricting factor in the development of immune therapies.</p> |
| first_indexed | 2024-04-23T08:23:58Z |
| format | Journal article |
| id | oxford-uuid:6346d878-02a9-4c12-ab40-6fa666183c89 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-04-23T08:23:58Z |
| publishDate | 2021 |
| publisher | Wolters Kluwer |
| record_format | dspace |
| spelling | oxford-uuid:6346d878-02a9-4c12-ab40-6fa666183c892024-04-11T15:13:19ZHypoxia-inducible factor 1 alpha-mediated RelB/APOBEC3B down-regulation allows hepatitis B virus persistenceJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6346d878-02a9-4c12-ab40-6fa666183c89EnglishSymplectic ElementsWolters Kluwer2021Riedl, TFaure-Dupuy, SRolland, MSchuehle, SHizir, ZCalderazzo, SZhuang, XWettengel, JLopez, MABarnault, RMirakaj, VProkosch, SHeide, DLeuchtenberger, CSchneider, MHeßling, BStottmeier, BWessbecher, IMSchirmacher, PMcKeating, JAProtzer, UDurantel, DLucifora, JDejardin, EHeikenwalder, M<p><strong>Background and Aims:</strong> Therapeutic strategies against HBV focus, among others, on the activation of the immune system to enable the infected host to eliminate HBV. Hypoxia‐inducible factor 1 alpha (HIF1α) stabilization has been associated with impaired immune responses. HBV pathogenesis triggers chronic hepatitis‐related scaring, leading inter alia to modulation of liver oxygenation and transient immune activation, both factors playing a role in HIF1α stabilization.</p> <p><strong>Approach and Results:</strong> We addressed whether HIF1α interferes with immune‐mediated induction of the cytidine deaminase, apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B; A3B), and subsequent covalently closed circular DNA (cccDNA) decay. Liver biopsies of chronic HBV (CHB) patients were analyzed by immunohistochemistry and in situ hybridization. The effect of HIF1α induction/stabilization on differentiated HepaRG or mice ± HBV ± LTβR‐agonist (BS1) was assessed in vitro and in vivo. Induction of A3B and subsequent effects were analyzed by RT‐qPCR, immunoblotting, chromatin immunoprecipitation, immunocytochemistry, and mass spectrometry. Analyzing CHB highlighted that areas with high HIF1α levels and low A3B expression correlated with high HBcAg, potentially representing a reservoir for HBV survival in immune‐active patients. In vitro, HIF1α stabilization strongly impaired A3B expression and anti‐HBV effect. Interestingly, HIF1α knockdown was sufficient to rescue the inhibition of A3B up‐regulation and ‐mediated antiviral effects, whereas HIF2α knockdown had no effect. HIF1α stabilization decreased the level of v‐rel reticuloendotheliosis viral oncogene homolog B protein, but not its mRNA, which was confirmed in vivo. Noteworthy, this function of HIF1α was independent of its partner, aryl hydrocarbon receptor nuclear translocator.</p> <p><strong>Conclusions:</strong> In conclusion, inhibiting HIF1α expression or stabilization represents an anti‐HBV strategy in the context of immune‐mediated A3B induction. High HIF1α, mediated by hypoxia or inflammation, offers a reservoir for HBV survival in vivo and should be considered as a restricting factor in the development of immune therapies.</p> |
| spellingShingle | Riedl, T Faure-Dupuy, S Rolland, M Schuehle, S Hizir, Z Calderazzo, S Zhuang, X Wettengel, J Lopez, MA Barnault, R Mirakaj, V Prokosch, S Heide, D Leuchtenberger, C Schneider, M Heßling, B Stottmeier, B Wessbecher, IM Schirmacher, P McKeating, JA Protzer, U Durantel, D Lucifora, J Dejardin, E Heikenwalder, M Hypoxia-inducible factor 1 alpha-mediated RelB/APOBEC3B down-regulation allows hepatitis B virus persistence |
| title | Hypoxia-inducible factor 1 alpha-mediated RelB/APOBEC3B down-regulation allows hepatitis B virus persistence |
| title_full | Hypoxia-inducible factor 1 alpha-mediated RelB/APOBEC3B down-regulation allows hepatitis B virus persistence |
| title_fullStr | Hypoxia-inducible factor 1 alpha-mediated RelB/APOBEC3B down-regulation allows hepatitis B virus persistence |
| title_full_unstemmed | Hypoxia-inducible factor 1 alpha-mediated RelB/APOBEC3B down-regulation allows hepatitis B virus persistence |
| title_short | Hypoxia-inducible factor 1 alpha-mediated RelB/APOBEC3B down-regulation allows hepatitis B virus persistence |
| title_sort | hypoxia inducible factor 1 alpha mediated relb apobec3b down regulation allows hepatitis b virus persistence |
| work_keys_str_mv | AT riedlt hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT fauredupuys hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT rollandm hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT schuehles hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT hizirz hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT calderazzos hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT zhuangx hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT wettengelj hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT lopezma hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT barnaultr hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT mirakajv hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT prokoschs hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT heided hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT leuchtenbergerc hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT schneiderm hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT heßlingb hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT stottmeierb hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT wessbecherim hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT schirmacherp hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT mckeatingja hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT protzeru hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT duranteld hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT luciforaj hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT dejardine hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence AT heikenwalderm hypoxiainduciblefactor1alphamediatedrelbapobec3bdownregulationallowshepatitisbviruspersistence |